Notes

Cohort report: Epigenetics while being pregnant (EPIPREG) -- population-based trial involving Western european and also Southern Hard anodized cookware expectant women using epigenome-wide DNA methylation (850k) in side-line blood leukocytes.
Introduction The Patient Dignity Inventory (PDI) is a reliable screening instrument for a variety of problems (physical, existential, and social) that affect the dignity of patients during their end of life. The PDI has been translated into several different languages and has been validated in different settings. As such, it is important to validate the instrument in patients with cancer in Mexico to assess dignity in this population. The aim of this study was to translate and validate the Spanish version of the PDI in Mexican patients with cancer. Methods This is a cross-sectional study that included patients with cancer, both those enrolled and not enrolled in palliative care, at the Instituto Nacional de Cancerología in Mexico City from September 2018 to August 2019. A translation and back translation were performed to obtain the Mexican version of the PDI (PDI-Mx) instrument. Patients completed the PDI-Mx, the Hospital Anxiety and Depression Scale (HADS), and functional scales (Eastern Cooperative Oncology Group [ECOG] and Karnofsky). Psychometric properties were evaluated by determining internal consistency, exploratory and confirmatory factor analysis (CFA), and concurrent validity with the HADS. Results We included 290 participants with cancer (145 in palliative care and 145 not enrolled in palliative care). The Cronbach's alpha of the PDI-Mx was 0.95. There was a significant correlation with the HADS (rs = 0.757, p  less then  0.0001). The factor analysis showed four factors that explain 64.7% of the model. The CFA presented adequate indicators, which show the adjustment of the structure that indicates a balanced and parsimonious model. Conclusions The Mexican version of the PDI shows adequate psychometric properties in patients with cancer. We suggest the use of PDI-Mx in clinical care and research. The study was approved by the Institutional Review Board and Ethics Committee with numbers (016/063/CPI) and (CEI/1115/16) respectively.Background Exercise training provides physiological benefits for maintaining good health. A common exercise strategy is high-intensity interval training (HIIT). HIIT may alleviate metabolic syndrome (MetS) and hypertriglyceridemic waist (HTGW) phenotype, but remains largely unstudied in ageing participants. The aim of this research was to investigate the impact of 2 weekly HIIT sessions on MetS markers and HTGW-related factors in older adults. Methods In this randomized controlled trial, 140 older men and women were randomized into two groups, the experimental group (EG), and the control group (CG). Compound 43 The EG performed 2 weekly sessions of HIIT during 12 weeks. HIIT sessions consisted of 40 min treadmill running/walking a 10 min warm-up at 50%-60% of maximum heart rate (HRmax), followed by 10 sets of 1 min bouts at 85%-90% of HRmax interspersed with 1 min walking at self-selected pace (totaling 20 min), and 10 min cool-down walking at self-selected pace. The CG did not perform any type of intense exercise during the intervention period. Results Participants in the EG of both sexes decreased MetS, HTGW, blood pressure, cholesterol, and glycemia (P  less then  0.05). After training, the number of hypertensive men decreased by 100% and women by 70%. There was a 75% reduction in women with diabetes, a 100% reduction in MetS indicators and over 80% reduction in HTGW in participants of both sexes. Conclusion Two weekly sessions of HIIT proved to be feasible and effective to induce clinically relevant improvements in MetS and HTGW indicators.Purpose This study investigated the safety and therapeutic efficacy of licarin A (LCA) in the treatment of intraocular inflammation. Methods In vitro safety of LCA in retinal pigmented epithelial cells (ARPE-19) and human embryonic stem cell derived-retinal pigmented epithelial cells (hES-RPE) was evaluated using CellTiter-Blue® kit. The chorioallantoic membrane (CAM) assay was used to investigate LCA safety and antiangiogenic activity. In vivo safety of intravitreal LCA was accomplished by clinical examination (including assessment of intraocular pressure), electroretinography (ERG), and histopathology. Uveitis was induced in rats by subcutaneous and intravitreal injection of bacillus Calmette-Guérin (BCG) antigen of Mycobacterium bovis. Intraocular inflammation was graded by slit-lamp and fundus examination, ERG, and histopathology. Results LCA was safe to cells and to the CAM at concentration below 12.0 μM. LCA significantly reduced the percentage of blood vessels in the CAM. Retinal safety and anti-inflammatory efficacy of intravitreal injection of LCA 6.0 μM were confirmed through clinical, functional, and histopathological evaluation. Significant reduction of inflammatory cytokines (tumor necrosis factor-α and interleukin-6) was also found, when compared to untreated animals. Conclusion The results suggest that LCA is a potential new drug for the treatment of inflammatory eye disease.Background Obstructive patients may benefit from nasal high-flow (NHF) therapy, but the use of pressurized metered-dose inhalers (pMDIs) has not been evaluated in this situation. Methods Using an adult circuit and medium-sized cannula, we have tested different NHF rates, pMDI positions, breathing patterns, spacers, and spacer orientation. First, we evaluated albuterol delivery at the nasal cannula outlet. The second set of experiments made use of a nasopharyngeal cast to estimate the mass of albuterol potentially reaching the lungs. Albuterol was caught on filters placed at the cannula outlet and downstream of the nasal cast, and albuterol was quantified by spectrophotometry. Results The highest amounts of albuterol delivered at the cannula outlet were observed with a 30 L/min flow rate (vs. 45 and 60 L/min) and placing the device close to the nasal cannula (in comparison with a position on the dry side of the humidification chamber). The use of a spacer was associated with higher delivery. The highest albuterol delivery was observed placing the spacer close to the nasal cannula, oriented for aerosol delivery following the gas flow and a 30 L/min NHF rate. Using this optimal setting, activating the pMDI at the beginning of inspiration (compared to expiration) increased albuterol delivery downstream of the nasopharyngeal cast. Whether in a quiet- or distress-breathing pattern, our measurements showed an amount of albuterol potentially delivered to the lungs exceeding 10% of the actuated dose in optimal conditions. Conclusions The use of pMDIs is feasible to deliver albuterol within a NHF circuit. Using a spacer placed just upstream from the nasal cannulas, a low NHF rate and activating the pMDI at the beginning of inspiration was associated with drug delivery susceptible to induce bronchodilation, which will require to be tested in the clinical setting.
Website: https://www.selleckchem.com/products/cp-43.html